65,437 trials
Major Depressive Disorder
Primary: Change From Baseline in Baseline-adjusted (Montgomery-Asberg Depression Scale) MADRS Score at the End of Treatment. — -6.1396; -6.0076; -11.3762 Scores on a scale
Chronic Iron Overload
Primary: CL/F — 8.3 litre/h
Primary Insomnia
Primary: Number of Metabolites Elevated Relative to the Other Group. — 13; 9 Number of metabolites elevated
Squamous Cell Carcinoma of the Head and Neck
Primary: Overall Survival (OS) — 7.49; 5.06 Months — p=0.0101
Acne
Primary: Absolute Change in Inflammatory Lesion Count — 16.3; 8.2 Lesion count
Dyspepsia · Helicobacter Pylori Infection
Primary: The Occurrence of H. Pylori Eradication as Confirmed Via 13C UBT Testing — 59; 1; 7; 36 Participants — p=0.001
Perinatal Outcome
Primary: Umbilical Cord pH — 7.29; 7.32 pH — p=0.1
Contact Lens Base Curve (BC) Fit and Comfort
Primary: Correlation Between Subjective CLUE Comfort and Keratometry — 0.042; 0.004; -0.001; -0.002 Pearson Correlation
Effect of Taxes and Subsides on Food Purchases in Mothers
Primary: Change in Energy Purchased as a Result of Taxes. — 10622.09; 10507.62; 10311.12; 10401.13 Total Calories Purchased
Interstitial Cystitis · Pelvic Pain
Primary: Change in Symptom Severity at 4 and 8 Weeks Post-Treatment as Measured by the Total O'Leary-Sant IC Symptom and Problem Index (ICSI/ICPI) Score — -4; -4 units on a scale
Myopia · Refractive Error
Primary: Corneal Epithelial Immune Dendritic Cell Density (Central Cornea) — 46.2; 44.8; 62.3 cells/mm2
Diabetes Mellitus, Type 2, Cancer
Primary: Hazard Ratio of the 10 Most Common Cancers Associated With Ever Use of Pioglitazone — 1.13; 1.00; 1.00; 0.91 Ratio
Pancreatic Cancer
Primary: Percentage of Participants With Adverse Events (AEs) — 78.8 percentage of participants
Brain Disease
Primary: Global Diagnostic Preference Between the Two Exams — 31; 51; 43; 14 participant exams — p=<0.0001
Serious Mental Illness
Primary: Positive and Negative Symptom Scale (PANSS) — 1.9; 1.8 units on a scale